figshare
Browse
13058_2021_1390_MOESM1_ESM.docx (280.08 kB)

Additional file 1 of RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Download (280.08 kB)
journal contribution
posted on 2021-03-31, 03:43 authored by Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez
Additional file 1: Figure S1. TMA H-scores and controls. A. RANK and RANKL H-scores in HER2-positive breast cancer samples, treatment-naïve (left panels) or anti-HER2-resistant (right panels). In treatment-naïve TMAs, each number represents a “core” from a single patient. In anti-HER2-resistant TMAs, scored independent tumor cores are numbered for each patient (after the symbol #). B. Representative pictures of human breast tumors from patient-derived xenografts used as positive and negative controls for RANK and RANKL IHC.

Funding

Fundació la Marató de TV3 (ES) Ministerio de Ciencia, Innovación y Universidades Susan G. Komen Instituto de Salud Carlos III Breast Cancer Research Foundation (US) European Research Council Fundación Científica Asociación Española Contra el Cáncer

History

Usage metrics

    Breast Cancer Research

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC